Testing Sinemet CR for Early Diabetic Retinopathy in Adults with Diabetes
Tests whether Sinemet CR slows early eye blood vessel changes in adults with diabetes.
Plain-language title generated from the registry record
Registry title: Treating Early Stage Diabetic Retinopathy
Key facts
- Where
- Decatur, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 80 years old?
Source: NCT05132660, who can take part
Where in United States
- Atlanta VA Medical and Rehab Center, Decatur, GADecatur, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- VA Office of Research and Development
- Trial code
- NCT05132660
- Record updated
- 7 April 2026
- Original description
To determine if levodopa will slow the appearance of blood vessel changes in the eyes of patients with diabetes. Treatment will be started in patients with diabetes show delays in the electrical activity of the retina when measured non-invasively with a electroretinogram.Read full original descriptionShow less
Treating Early Stage Diabetic Retinopathy
To determine if levodopa will slow the appearance of blood vessel changes in the eyes of patients with diabetes. Treatment will be started in patients with diabetes show delays in the electrical activity of the retina when measured non-invasively with a electroretinogram.
Inclusion: HbA1c 8-12%; Diabetic patients with no retinopathy as screened with teleretinal imaging; Diabetic patients with microaneurysms as detected with fundus teleretinal screening; ERG oscillatory potential delays in response to dim flash stimuli.
Exclusion: No anti-VEGF or steroid treatments within the last 12 months; Patients with pituitary tumor, psychosis, Parkinson's disease; Patients with confounding ocular disease (visually significant cataract, glaucoma, macular degeneration, retinitis pigmentosa); Patients with cognitive deficits (score of 24 or less on the Montreal Cognitive; Assessment-MOCA; Pregnancy.